Genitourinary Cancers Symposium is organized by American Society of Clinical Oncology (ASCO) and will be held during Feb 08 - 10, 2018 at Moscone Center, San Francisco, California, United States of America.
The target audience for this medical event is physicians and researchers interested in the prevention, screening, evaluation, and management of genitourinary cancers, including, but not limited to medical, surgical, and radiation oncologists; pathologists; radiologists; and other translational-oriented laboratory scientists. This CME Conference has been approved with a maximum of 26.00 AMA PRA Category 1 Credits.
This symposium gives healthcare providers across multiple disciplines and professions the opportunity to receive critical updates and recommendations to improve the care of patients with these cancers. Although incidence and mortality rates for many cancers in this area seem difficult to decrease, emerging science offers new options for multidisciplinary precision care through new and emerging diagnostic approaches, as well as innovative therapy options. Continued evolution in the clinical evidence base highlights the ongoing need for education in this area to ensure that all members of the cancer care team can inform themselves in how best to integrate emerging therapies and diagnostic technologies given the options currently available.
This is a three-day scientific and educational meeting designed to meet the needs of physicians and other members of the cancer care and research community who diagnose, treat, and study GU malignancies. In educational sessions, expert faculty will discuss new research and its clinical application with an emphasis on multidisciplinary care across the spectrum of GU cancers. Oral abstract presentations and poster sessions will highlight the latest, cutting-edge science, and keynote lectures from internationally renowned speakers will address the most clinically relevant research in the field of GU oncology.
Conference objectives are : -
Upon participation in this activity, attendees will be able to
• Collaborate across different specialties and with all members of the oncology care team to provide effective and patient-centered treatment and supportive care for patients with genitourinary cancers
• Examine the growing use of immunotherapeutic agents in the treatment of patients with genitourinary cancers, to include both approved clinical indications and ongoing clinical research, and highlight changes for diagnostic approaches as well as changes for treatment decisions and overall patient management
• Evaluate and interpret best available current evidence, including recent clinical trials, to inform treatment decisions where multiple therapeutic options exist for a patient with a genitourinary cancer
• Outline the genomic tests that are currently available based on existing evidence or in clinical trials, describing the potential impact of biomarkers for diagnosis and therapy selections as well as the potential impact of tumor heterogeneity on treatment decisions and plans for disease monitoring
• Discuss the increasing diversity of clinical scenarios where precision imaging can provide diagnostic or prognostic benefit for patients with genitourinary cancers, including use in evaluating indeterminate and post-chemotherapy masses
• Describe the optimal uses of hormone therapies in patients with hormone-responsive genitourinary cancers and the accurate interpretation of endocrinology data to manage treatment more effectively.
Additional details will be posted as soon as they are available.
|Contact No.||:||(571) 483-1300|
|Registration Type||Due Date||Price|
|Nonmember physician - Early Fee||03 Jan,2018||USD 895.00|
|Nonmember physician who is in the first three years of practice after fellowship or residency - Early Fee||03 Jan,2018||USD 620.00|
|Nonmember scientist or health professional at the postgraduate level (PhD, PharmD) - Early Fee||03 Jan,2018||USD 670.00|
|Nonmember oncology fellow, resident, or postdoctoral fellow - Early Fee||03 Jan,2018||USD 470.00|
|Nonmember advanced practice provider, genetic counselor, nurse, pharmacist, physician assistant, or practice administrator - Early Fee||03 Jan,2018||USD 620.00|
|Nonmember research assistant or social worker - Early Fee||03 Jan,2018||USD 470.00|
|Nonmember - Emeritus or retired - Early Fee||03 Jan,2018||USD 470.00|
|Nonmember student - Early Fee||03 Jan,2018||USD 210.00|
|Nonmember non-oncology resident or fellow, including internal medicine residents - Early Fee||03 Jan,2018||USD 470.00|
|Nonmember patient advocate - Early Fee||03 Jan,2018||USD 280.00|
|All other nonmembers - Early Fee||03 Jan,2018||USD 895.00|
|Member physician - Early Fee||03 Jan,2018||USD 620.00|
|Member physician who is in the first three years of practice after fellowship or residency - Early Fee||03 Jan,2018||USD 470.00|
|Member scientist or health professional at the postgraduate level (PhD, PharmD) - Early Fee||03 Jan,2018||USD 520.00|
|Member oncology fellow, resident, or postdoctoral fellow - Early Fee||03 Jan,2018||USD 280.00|
|Member advanced practice provider, genetic counselor, nurse, pharmacist, physician assistant, or practice administrator - Early Fee||03 Jan,2018||USD 470.00|
|Member research assistant or social worker - Early Fee||03 Jan,2018||USD 330.00|
|Member - Emeritus or retired - Early Fee||03 Jan,2018||USD 270.00|
|Member student - Early Fee||03 Jan,2018||USD 85.00|
|Member non-oncology resident or fellow, including internal medicine residents - Early Fee||03 Jan,2018||USD 330.00|
|Member patient advocate - Early Fee||03 Jan,2018||USD 280.00|
|All other Members - Early Fee||03 Jan,2018||USD 620.00|